Federated Hermes, Inc. T Scan Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$43.9 Billion
Q1 2025

A detailed history of Federated Hermes, Inc. transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 2,182 shares of TCRX stock, worth $4,102. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,182

Holding current value

$4,102

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2025 May 08, 2025	BUY	$1.35 - $3.12 $2,945 - $6,807	2,182 New	2,182 $3,000
Q1 2024 May 14, 2024	BUY	$4.89 - $8.3 $273 - $464	56 New	56 $0

Others Institutions Holding TCRX

# of Institutions

Shares Held

39.8M

Call Options Held

Put Options Held

Lynx1 Capital Management LP San Juan, PR

5.36M
Shares

$10.1 Million
2.73% of portfolio
Bvf Inc San Francisco, CA

4.89M
Shares

$9.19 Million
0.3% of portfolio
Black Rock Inc. New York, NY

4.46M
Shares

$8.39 Million
0.0% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

3.5M
Shares

$6.58 Million
0.01% of portfolio
Baker Bros. Advisors LP New York, NY

2.78M
Shares

$5.24 Million
0.05% of portfolio

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $35.6M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account